KLRB1 and neoplasm: Recent studies have reported that CD161 is a glioblastoma inhibitory immune checkpoint and blocking CD161 receptors on tumor‐infiltrating T cells enhances their immune effects and tumor‐killing potency in vivo and in vitro [22].